0000000000587543
AUTHOR
L. Almenar Bonet
Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels
Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …
Consenso sobre el manejo de la hiperpotasemia en pacientes con insuficiencia cardíaca: recomendaciones de la SEC-SEMI
Resumen En los pacientes con insuficiencia cardiaca (IC) y fraccion de eyeccion reducida, el uso de los inhibidores del sistema renina-angiotensina-aldosterona (iSRAA) se asocia con una mejoria funcional, incremento de la calidad de vida percibida, reduccion de la probabilidad de muerte cardiovascular y disminucion del numero de hospitalizaciones. Algunos de esos farmacos tambien resultan eficaces en pacientes con enfermedad renal cronica y albuminuria, asi como en pacientes con hipertension arterial resistente. A pesar de sus numerosos beneficios, los iSRAA se asocian a un incremento de la incidencia de hiperpotasemia, sobre todo en pacientes con insuficiencia renal cronica concomitante. L…
Consensus on the management of hyperkalemia in patients with heart failure: Recommendations from the SEC-SEMI
Abstract Use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure (HF) and reduced ejection fraction is associated with functional improvement, an increase in perceived quality of life, a reduction in the probability of cardiovascular death, and a decrease in the number of hospitalizations. Some of these drugs are also efficacious in patients with chronic kidney disease and albuminuria as well as in patients with resistant hypertension. Despite their numerous benefits, RAASi are associated with an increase in incidence of hyperkalemia, especially in patients with concomitant chronic kidney disease. Hyperkalemia is a common electrolyte disorder that is de…